Cancer Registry Software Market Size, Share & Trends Analysis Report By Software (Standalone, Integrated), By Deployment (On-premise, Cloud-Based), By Component (Commercial, Public), By End-User (Government & Third Party, Private Payers, Hospital & Medical Practice, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Cancer Registry Software Market Size

The global cancer registry software market size was valued at USD 98.11 million in 2025 and is projected to grow from USD 107.43 million in 2026 to USD 222.04 million by 2034, registering a CAGR of 9.5% during the forecast period from 2026 to 2034. North America dominated the cancer registry software market with a market share of 41.2% in 2025.

Cancer registry software is a specialized digital solution designed to collect, manage, and analyze cancer-related data, supporting research, treatment planning, and public health initiatives. It enables healthcare providers, researchers, and government agencies to track oncologic disease incidence, treatment outcomes, and survival rates. By integrating patient records, pathology reports, and genetic data, the software facilitates early detection, epidemiological studies, and personalized treatment strategies.

The market is experiencing significant growth, driven by the rising global incidence of oncologic disease, the increasing need for efficient data management in oncology, and advancements in healthcare IT solutions. Government initiatives to strengthen cancer surveillance, the seamless integration of EHRs, and growing investments in research and development are further propelling market expansion. Moreover, the adoption of cloud-based technologies and AI-driven analytics is revolutionizing cancer data management and enhancing patient outcome tracking.

According to the data mentioned above, breast cancer accounted for the highest number of new cases in 2022, witnessing an 11.60% increase. This rising oncologic disease incidence underscores the urgent need for efficient data management solutions to support healthcare professionals, researchers, and various other sectors in maintaining comprehensive cancer-related records. The growing demand for sophisticated registry software equipped with automation, predictive analytics, and real-time reporting is further driving market expansion.

Software Insights

The standalone segment leads the global market due to its customized features and user-friendly interface for efficient cancer data management. This software is designed with advanced data entry, tracking, and reporting tools, making it ideal for specialized oncologic disease registries.

• In July 2023, Susan G. Komen launched ShareForCures, a cloud-based breast cancer registry enabling patients to securely share health data for research, addressing data gaps and improving diversity in oncologic disease studies.

Request Customizationto receive a tailored report.

Deployment Insights

On-premises dominates the market, offering greater control over data security, compliance, and customization crucial for managing sensitive cancer patient records. Hospitals and research institutions prefer on-premises solutions to store data internally, reducing risks from third-party access. Moreover, organizations with robust IT infrastructure favor on-premises deployment for seamless integration with existing systems. This ensures effective data management while maintaining strict regulatory compliance, reinforcing its position as the preferred deployment model in the market.

Component Insights

Commercial leads the global cancer registry software market due to its high-end features, customization options, and comprehensive data management capabilities. These solutions offer seamless integration with healthcare systems, real-time updates, and dedicated customer support, making them the preferred choice for hospitals and research centers. Commercial software providers continuously enhance their platforms with AI-driven analytics and automation tools, further improving efficiency in oncologic disease data tracking, reporting, and patient outcome analysis, driving their dominance in the market.

End-User Insights

Governments and third-party organizations lead the market for cancer registry software due to their role in national oncologic disease control programs, regulatory compliance, and significant investments in healthcare infrastructure.

• In August 2024, the Surveillance, Epidemiology, and End Results (SEER) Program was highlighted as a key initiative in cancer data collection and analysis.

According to the National Cancer Institute (NCI), SEER covers 48% of the U.S. population, serving as an essential tool for researchers, public health officials, and policymakers, driving market growth.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America dominates the global market, driven by advanced healthcare infrastructure, widespread adoption of digital health solutions, and strong government support for cancer surveillance programs. The U.S. Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI) and the National Program of Cancer Registries (NPCR) by the Centers for Disease Control and Prevention (CDC) have significantly improved data collection and reporting, with NPCR funding 50 cancer registries. Moreover, rising investments in oncology research, the presence of major market players, and growing awareness about oncologic disease prevention contribute to the region’s market leadership.

The United States dominates the market due to the rising prevalence of cancer and the growing survivor population. A July 2024 study in the Journal of the National Cancer Institute reported 18.1 million oncologic disease survivors in 2022, with 70% living beyond five years post-diagnosis. This surge drives demand for advanced registry software to track treatment outcomes, manage follow-up care, and enhance data-driven oncologic disease research.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Cancer Registry Software Market Trends

Asia-Pacific is expected to witness the fastest CAGR in the global cancer registry software market, fueled by increasing oncologic disease prevalence, healthcare infrastructure investments, and the rising adoption of digital health technologies. Countries like Japan, China, and Australia are heavily investing in cancer surveillance systems to improve early detection and treatment outcomes. For example, China’s National Central Cancer Registry of China (NCCR) plays a crucial role in managing extensive data, supporting research and treatment strategies, and enhancing data accuracy through advanced registry software.

China’s vast population and rising cancer prevalence fuel its growing market. In April 2023, China reported significant advancements in cancer registration software, tracking incidence, survival, and mortality rates to guide research and prevention efforts. The country’s five-year oncologic disease survival rate improved from 30.9% to 40.5% over the past decade, highlighting the critical role of advanced registry software in enhancing patient care and research capabilities.

India is experiencing rapid market expansion, supported by government-led cancer registry programs. In January 2025, the country launched its first population-based childhood oncologic disease registry in Chennai, reporting an incidence rate of 136 per million for 2022–2023. The two-year survival rate stood at 60%, rising to 70% for high-resolution data cases. This initiative strengthens cancer-stage reporting and treatment tracking, increasing the demand for advanced registry software across India.

Japan’s market is expanding due to strong regulatory approvals and government initiatives. In December 2024, the SCRUM-Japan Registry played a pivotal role in securing the world’s first approval for HER2-positive colorectal oncologic disease, as highlighted in a study. The growing use of cancer registry data in regulatory filings is driving demand for advanced software solutions, reinforcing Japan’s role as a key player in the global cancer registry market.

Europe Cancer Registry Software Market Trends

Germany is a key player in the cancer registry software, driven by government policies and regulatory support. A 2023 study in Cancers highlighted the success of Germany’s population-based clinical cancer registration, facilitated by a federal law mandating standardized electronic data collection. This integration has improved quality assurance and feedback for healthcare providers, increasing demand for cancer registry software and strengthening Germany’s market position.

Competitive Landscape

Key players in the cancer registry software market are actively adopting strategic initiatives such as collaborations, product approvals, acquisitions, and new product launches to strengthen their market presence. Companies are focusing on enhancing software capabilities through AI-driven analytics, cloud-based solutions, and interoperability with healthcare systems.

Coopersurgical Inc.: An Emerging Player in the Global Cancer Registry Software Market

CooperSurgical Inc. is a leading healthcare company specializing in fertility, women’s health, and medical devices. Founded in 1990 and headquartered in Connecticut, U.S., the company offers an extensive portfolio of innovative products and services designed to enhance reproductive health, prenatal care, and surgical solutions.

List of Key and Emerging Players in Cancer Registry Software Market